

# **EVALUATION OF ANTIDIABETIC EFFECT OF BERBERINE IN TYPE 2 DIABETIC RATS MODELS**

**Thesis**

*Submitted for partial fulfillment of M.D. degree In Medical Physiology*

**By**

**Marwa Mohamed Abd Elrahman**

*M.Sc Physiology*

*Under supervision of*

**Prof. Dr. Hassan Mohamed Eissa**

*Professor of Physiology*

*Faculty of Medicine- Cairo University*

**Dr. Nermeen Abdallah Bastawy**

*Lecturer of Physiology*

*Faculty of Medicine - Cairo University*

**Dr. Ayman Mahmoud Moawad**

*Lecturer of Zoology*

*Faculty of Science - Beni Suef University*

**Faculty of Medicine**

**Cairo University**

**(2016)**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



## *Acknowledgement*

*First of all, I'm greatly indebted to **Allah** whose grace, power and care safe-guarded my path towards achieving this thesis.*

*Heartily, it is my pleasure to express my deep gratitude and sincere appreciation to **Prof. Dr. Hassan Mohamed Eissa**, Professor of Physiology, Faculty of Medicine, Cairo University, for his good choice to this problem, planning of the work beside the guidance in all steps of this thesis. Also for reading and correcting the manuscript and supplying me with a lot of information and support.*

*I wish also to express my deep gratitude and very special thanks to **Dr. Nermeen Abdallah Bastawy**, Lecturer of Physiology, Faculty of Medicine, Cairo University, for her keen supervision, suggesting the problem, planning and guidance the work, reading and criticizing the manuscript, continuous encouragement and the facilities she offered.*

*I will be happy to thank **Dr. Ayman Mahmoud Moawad**, Lecturer of Zoology, Faculty of Science, Beni Suef University, for his continuous encouragement and valuable support throughout the present study.*

*Last but not least, I wish to express my deep thanks and gratitude to my family for constant help and encouragement.*

*I owe much to them all for their kindness and continuous sincere guidance throughout the course of this work.*

## *List of Contents*

	Page
<b>List of Abbreviations</b>	
<b>List of Tables</b>	
<b>List of Figures</b>	
<b>Introduction &amp; Aim of Work</b>	<b>1</b>
<b>Review of Literature</b>	
<b>Chapter (1):</b>	<b>4</b>
• <b>Diabetes Mellitus</b>	
<b>Chapter (2):</b>	
• <b>Berberine</b>	<b>21</b>
<b>Materials and Methods</b>	<b>34</b>
<b>Results</b>	<b>52</b>
<b>Discussion</b>	<b>95</b>
<b>Summary</b>	<b>113</b>
<b>References</b>	<b>118</b>
<b>Arabic Summary</b>	

## **ABSTRACT**

Berberine exists in a number of medicinal plants and displays many pharmacological effects on type 2 diabetes mellitus. The study aimed to determine the hypoglycemic effects of berberine in rats with type 2 diabetes, on inflammatory biomarkers, insulin, adiponectin, lipid profile, liver oxidative stress biomarkers, mRNA expression levels of PPAR $\gamma$  and resistin. Diabetes was induced by feeding rats with high fat diet for 4 weeks followed by injection of STZ, Oral doses of 50 and 100 mg/kg berberine were daily given for 4 weeks after diabetes induction.

**Key Words:-** Berberine - type 2 diabetes – insulin resistance.

## *List of Abbreviations*

4-AP	4-aminophenazone
A	Absorbance
AD	Alzheimer's disease
ADA	American Diabetes Association
AAI	Antiatherogenic index
Akt	Protein kinase B
ALT	Alanine aminotransferase
AMPK	Adenosine monophosphate kinase
ANOVA	Analysis of variance
AST	Aspartate aminotransferase
BBR	Berberine
CAT	Catalase
cDNA	Complimentary DNA
CHD	Coronary heart disease
CK-MB	Creatine kinase MB
CMC	Carboxy methyl cellulose
COX-2	Cyclooxygenase-2
DNA	Deoxyribonucleic acid
DTNB	5,5'dithiobis (2-nitrobenzoic acid)
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
ERK	Extracellular-signal-regulated kinase
FBS	Fetal bovine serum
FFA	Free fatty acids
FPG	Fasting plasma glucose
GK	Glycerol kinase
GLP	Glucagon like peptide

<b>GLUT</b>	<b>Glucose transporter</b>
<b>GPO</b>	<b>Glycerol-3-phosphate oxidase</b>
<b>GPx</b>	<b>Glutathione peroxidase</b>
<b>GR</b>	<b>Glutathione reductase</b>
<b>GSH</b>	<b>Reduced glutathione</b>
<b>H<sub>2</sub>O<sub>2</sub></b>	<b>Hydrogen peroxide</b>
<b>HDAC3</b>	<b>Histone deacetylase-3</b>
<b>HDL</b>	<b>High density lipoprotein</b>
<b>HFD</b>	<b>High fat diet</b>
<b>HOMA-IR</b>	<b>Homeostasis model assessment of insulin resistance</b>
<b>IC</b>	<b>Inhibitor concentration</b>
<b>IDDM</b>	<b>Insulin-dependent diabetes mellitus</b>
<b>IGF-1</b>	<b>Insulin-like growth factor 1</b>
<b>IL</b>	<b>Interleukin</b>
<b>INF</b>	<b>Interferon</b>
<b>iNOS</b>	<b>Inducible nitric oxide synthase</b>
<b>ip</b>	<b>Intraperitoneal</b>
<b>IR</b>	<b>Insulin receptors</b>
<b>IRS</b>	<b>Insulin receptor substrate</b>
<b>LDH</b>	<b>Lactate dehydrogenase</b>
<b>LDL</b>	<b>Low density lipoprotein</b>
<b>LDLR</b>	<b>Low density lipoprotein receptor</b>
<b>LPL</b>	<b>Lipoprotein lipase</b>
<b>LPL</b>	<b>Lipoprotein lipase</b>
<b>MAPK</b>	<b>Mitogen-activated protein kinase</b>
<b>MDA</b>	<b>Malondialdehyde</b>
<b>MDH</b>	<b>Malate dehydrogenase</b>
<b>mRNA</b>	<b>Messenger RNA</b>
<b>NAD</b>	<b>Nicotinamide adenine dinucleotide</b>

<b>NADH</b>	<b>Nicotinamide adenine dinucleotide +Hydrogen</b>
<b>NF-κB</b>	<b>Nuclear factor kappa-B</b>
<b>NO</b>	<b>Nitric oxide</b>
<b>NOD</b>	<b>Nonobese diabetic</b>
<b>NOS</b>	<b>Nitric oxide synthase</b>
<b>Nrf2</b>	<b>Nuclear factor erythroid-2-related factor-2</b>
<b>OD</b>	<b>Optical Density</b>
<b>OGTT</b>	<b>Oral glucose tolerance test</b>
<b>PCR</b>	<b>Polymerase chain reaction</b>
<b>PI-3K</b>	<b>Phosphatidylinositol 3-kinase</b>
<b>PKB</b>	<b>protein kinase B</b>
<b>POD</b>	<b>Peroxidase</b>
<b>PPAR</b>	<b>Peroxisome proliferator activated receptor</b>
<b>PPREs</b>	<b>PPAR response element</b>
<b>r.p.m</b>	<b>Round per minute</b>
<b>RNA</b>	<b>Ribonucleic acid</b>
<b>RNS</b>	<b>Reactive nitrogen species</b>
<b>ROS</b>	<b>Reactive oxygen species</b>
<b>RT-PCR</b>	<b>Reverse transcriptase polymerase chain reaction</b>
<b>RXR</b>	<b>Retinoid X receptor</b>
<b>SD</b>	<b>Standard deviation</b>
<b>SEM</b>	<b>Standard error mean</b>
<b>SIRT1</b>	<b>Sirtuin</b>
<b>SOD</b>	<b>Superoxide dismutase</b>
<b>SREBP</b>	<b>Sterol regulatory element-binding protein</b>
<b>STAT</b>	<b>Signal transducer and activator of transcription</b>
<b>STZ</b>	<b>Streptozotocin</b>
<b>T2D</b>	<b>Type 2 diabetes</b>
<b>TBA</b>	<b>Thiobarbituric acid</b>



<b>TBARS</b>	<b>Thiobarbituric acid reacting substance</b>
<b>TCA</b>	<b>Trichloroacetic acid</b>
<b>Th</b>	<b>T helper</b>
<b>TNF-<math>\alpha</math></b>	<b>Tumor necrosis-factor alpha</b>
<b>UCP2</b>	<b>Uncoupling protein 2</b>
<b>VEGF</b>	<b>Vascular endothelial growth factor</b>
<b>vLDL</b>	<b>Very low density lipoprotein</b>
<b>WHO</b>	<b>World Health Organization</b>

## *List of Tables*

Table	Title	Page
1	Body weight changes in control, diabetic and diabetic rats treated with berberine.	54
2	Oral glucose tolerance test in control, diabetic and diabetic rats treated with berberine.	55
3	Area under curve analysis of OGTT.	56
4	Serum insulin and HOMA-IR in control, diabetic and diabetic rats treated with berberine.	58
5	Serum fructosamine and liver glycogen in control, diabetic and diabetic rats treated with berberine	61
6	Serum pro-inflammatory cytokines in control, diabetic and diabetic rats treated with berberine.	64
7	Serum adiponectin in control, diabetic and diabetic rats treated with berberine.	67
8	Lipid profile in control, diabetic and diabetic rats treated with berberine.	72
9	Cardiovascular risk indices and antiatherogenic index in control, diabetic and diabetic rats treated with berberine.	78
10	Serum AST, LDH and CK-B in control, diabetic and diabetic rats treated with berberine.	81
11	Liver lipid peroxidation and nitric oxide in control, diabetic and diabetic rats treated with berberine.	85
12	Liver reduced glutathione and antioxidant enzymes in control, diabetic and diabetic rats treated with berberine	89

## *List of Figures*

Fig.	Title	Page
1	Body weight changes in control, diabetic and diabetic rats treated with berberine.	54
2	Oral glucose tolerance test in control, diabetic and diabetic rats treated with berberine.	55
3	Area under curve analysis of OGTT.	56
4	Serum insulin levels in control, diabetic and diabetic rats treated with berberine.	58
5	HOMA-IR in control, diabetic and diabetic rats treated with berberine.	59
6	Serum fructosamine in control, diabetic and diabetic rats treated with berberine.	62
7	Liver glycogen in control, diabetic and diabetic rats treated with berberine.	62
8	Serum TNF- $\alpha$ cytokines in control, diabetic and diabetic rats treated with berberine.	65
9	Serum IL-6 cytokines in control, diabetic and diabetic rats treated with berberine.	65
10	Serum IL-1 $\beta$ cytokines in control, diabetic and diabetic rats treated with berberine.	66
11	Serum adiponectin in control, diabetic and diabetic rats treated with berberine.	68
12	Serum total cholesterol in control, diabetic and diabetic rats treated with berberine.	72
13	Serum triglycerides in control, diabetic and diabetic rats treated with berberine.	73

14	Serum HDL-cholesterol in control, diabetic and diabetic rats treated with berberine.	73
15	Serum LDL-cholesterol in control, diabetic and diabetic rats treated with berberine.	74
16	Serum vLDL-cholesterol in control, diabetic and diabetic rats treated with berberine.	74
17	Serum free fatty acids in control, diabetic and diabetic rats treated with berberine.	75
18	Cardiovascular risk index 1 in control, diabetic and diabetic rats treated with berberine.	78
19	Cardiovascular risk index 2 in control, diabetic and diabetic rats treated with berberine.	79
20	Antiatherogenic index in control, diabetic and diabetic rats treated with berberine.	79
21	Serum AST in control, diabetic and diabetic rats treated with berberine.	82
22	Serum LDH in control, diabetic and diabetic rats treated with berberine.	82
23	Serum CK-MB in control, diabetic and diabetic rats treated with berberine.	83
24	Liver lipid peroxidation in control, diabetic and diabetic rats treated with berberine.	86
25	Liver nitric oxide in control, diabetic and diabetic rats treated with berberine.	86
26	Liver reduced glutathione in control, diabetic and diabetic rats treated with berberine.	90
27	Liver superoxide dismutase activity in control, diabetic and diabetic rats treated with berberine.	90

28	Liver catalase activity in control, diabetic and diabetic rats treated with berberine.	91
29	Liver glutathione peroxidase activity in control, diabetic and diabetic rats treated with berberine.	91
30	RT-PCR analysis of adipose tissue PPAR $\gamma$ and $\beta$ -actin expression of control, diabetic and diabetic rats treated with berberine.	93
31	RT-PCR analysis of adipose tissue resistin and $\beta$ -actin expression of control, diabetic and diabetic rats treated with berberine.	94



# **INTRODUCTION**

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder caused by defects in insulin secretion, insulin action or both. If ineffectively controlled, the resulting chronic hyperglycaemia is associated with numerous disabling complications (**Tripathy and Chavez, 2010**). It is the most common form of the disease, which accounts for more than 90% of all diabetic patients (**Tripathi and Srivastava, 2006**). The incidence of diabetes is increasing worldwide and T2DM and its complications constitute a major public health problem (**Wu et al., 2014**). It is predicted that T2DM will continue to increase in developing countries with the majority of patients being 45-64 years old (**Wild et al., 2004**). Health spending on diabetes accounted for 10.8% of the total health expenditure worldwide and the disease caused 5.1 million deaths in 2013 (**International Diabetes Federation, 2013**). According to the International Diabetes Federation, the number of patients with diabetes mellitus in 2015 was estimated to be 415 million, and is expected to increase to 642 million by 2040 (**International Diabetes Federation, 2015**).

A wide variety of lifestyle factors, such as sedentary lifestyle (**Zimmet et al., 2001**), physical inactivity (**Hu et al., 2002**), smoking (**Manson et al., 2000**), and alcohol consumption (**Cullmann et al., 2012**), are of great importance to the development of T2DM. The main mechanisms of insulin resistance in T2DM are oxidative stress, endoplasmic reticulum stress, amyloid deposition in the pancreas, ectopic lipid deposition in the muscle, liver and pancreas, and lipotoxicity and glucotoxicity (**Weir and Bonner-Weir, 2004**). Although it is difficult to determine which mechanism is the most important, among those with



T2DM these processes can be caused by overnutrition. It is important to note, however, that each of these stresses could either induce an inflammatory response or be associated with inflammation (**Hotamisligil and Erbay, 2008**).

The association between inflammation and insulin resistance and future development of T2DM has been shown (**Donath et al., 2009**). The production of tumour necrosis factor (TNF)- $\alpha$  by cells in the adipose tissue of rodents provided early evidence of a link between tissue inflammation and the pathogenesis of insulin resistance and T2DM (**Hotamisligil et al., 1993**). In addition, interleukin (IL)-1 $\beta$  contributes to the glucose-induced impairment of  $\beta$ -cell function and apoptosis (**Maedler et al., 2002**).

Adipose tissue is now recognized as a secretory organ that plays important role in insulin sensitivity and energy expenditure (**Attie and Scherer, 2009**), and dysfunction in adipocytes is associated with insulin resistance and type 2 diabetes (**Blüher, 2009**). Adipocytes are understood to secrete diverse pro-inflammatory cytokines such as IL-6 and TNF- $\alpha$ , as well as anti-inflammatory cytokines such as adiponectin (**Sowers, 2008**). Increased levels of TNF- $\alpha$  and IL-6, and reduced level of adiponectin can exacerbate insulin resistance in adipose tissue (**Blüher, 2009**).

Berberine, an isoquinoline alkaloid originally isolated from the Chinese herb *Coptis chinensis* (Huanglian), is one of the main components of *R. coptidis* (**Leng et al. 2004**). Recent studies have demonstrated that berberine has remarkable effects as an anti-hyperglycemic and anti-hyperlipidemic, and it reduces weight gain in type 2 diabetes patients (**Yin et al. 2008a; Zhang et al. 2010 and Zhao et al. 2008**). Therefore, we have attempted to demonstrate the beneficial effects of berberine in